The 14.2% discount to market and immediate dilution of $13.95 per share signal near-term selling pressure. Monitor for potential further equity raises given the company's pre-commercial status and broad discretion over proceeds. The underwriters' 30-day option for additional shares adds overhang. Watch for any clinical catalysts (darovasertib NDA filing in H2 2026) that could offset dilution concerns.
Price Chart
Executive Summary
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, priced at $27.00 per share (and $26.9999 per pre-funded warrant). The offering represents roughly 6.3% dilution to existing shareholders based on shares outstanding as of March 31, 2026, and was priced at a 14.2% discount to the last closing price of $31.48. Proceeds will fund continued clinical development and potential commercialization of darovasertib for uveal melanoma, pipeline advancement, and general corporate purposes.
Key Facts
- Offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares at $27.00 per share/$26.9999 per warrant
- Net proceeds of approximately $281.3 million ($323.6 million if underwriters' option exercised in full)
- Priced at a 14.2% discount to the $31.48 closing price on June 8, 2026
- Immediate dilution of $13.95 per share to new investors; as-adjusted net tangible book value increases from $10.67 to $13.05 per share
- Underwriters have a 30-day option to purchase up to 1,666,669 additional shares
- Proceeds to fund darovasertib development, pipeline advancement, and general corporate purposes
- Lock-up agreements with directors and executive officers for 60 days post-offering
Financial Impact
~$300M gross offering; ~$282M net proceeds; ~6.3% dilution to existing shareholders based on 87.9M shares outstanding pre-offering
Risk Factors
- Immediate and substantial dilution to existing shareholders ($13.95 per share)
- Potential for further equity offerings given pre-revenue status and broad capital needs
- Underwriters' option for additional shares creates near-term overhang
- No guarantee that proceeds will enhance shareholder value given management's broad discretion
- Stock price volatility common in biotechnology sector
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-264032 |
| Document: d160204dexfilingfees.htm | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index-headers.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032.txt | 0001193125-26-264032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.36 (+3.46%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.36 (+2.98%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.36 (−29.54%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.36 (−35.36%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.36 (−33.10%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.36 (+31.55%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.36 (+29.99%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.36 (+29.99%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.36 (+13.83%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.36 (+20.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access